Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Safety and activity of ceralasertib in the treatment of MDS

Andrew M. Brunner, MD, Massachusetts General Hospital, Boston, MA, shares some insights into the safety and preliminary activity of ceralasertib, an ATR kinase inhibitor, in the treatment of patients with myelodysplastic syndromes (MDS). Patients with MDS often have a poor survival outcome and limited therapeutic options after they stop responding to azacitidine and decitabine, and Dr Brunner explains that splicing factor mutation also contributes to this disease. Dr Brunner then gives an overview of this mutation and the role of ATR kinase, and further explains the mechanism of action of ceralasertib. To conclude, Dr Brunner summarizes some results from this study, including the side effects and clinical activity observed in patients treated with ceralasertib, and how this agent may play an important role in the future of MDS treatment. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.


Keros Therapeutics: Consultancy; AstraZeneca: Research Funding; GSK: Research Funding; Aprea: Research Funding; Agios: Consultancy; Acceleron: Consultancy; Janssen: Research Funding; Takeda: Consultancy, Research Funding; BMS/Celgene: Consultancy, Research Funding; Novartis: Consultancy, Research Funding.